Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Dacuronium bromide

From Wikipedia, the free encyclopedia
(Redirected from Dacuronium)
Dacuronium bromide
Clinical data
Other namesNB-68; 17β-Hydroxypancuronium bromide; 3α-(Acetyloxy)-17β-hydroxy-2β,16β-bis(1-methylpiperidinium-1-yl)-5α-androstane dibromide; 2β,16β-Dipiperidino-5α-androstane-3α,17β-diol 3α-acetate dimethobromide
Identifiers
  • [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-Hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;dibromide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.043.834 Edit this at Wikidata
Chemical and physical data
FormulaC33H58Br2N2O3
Molar mass690.646 g·mol−1
3D model (JSmol)
  • CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5O)[N+]6(CCCCC6)C)C.[Br-].[Br-]
  • InChI=1S/C33H58N2O3.2BrH/c1-23(36)38-30-20-24-12-13-25-26(33(24,3)22-29(30)35(5)18-10-7-11-19-35)14-15-32(2)27(25)21-28(31(32)37)34(4)16-8-6-9-17-34;;/h24-31,37H,6-22H2,1-5H3;2*1H/q+2;;/p-2/t24-,25+,26-,27-,28-,29-,30-,31-,32-,33-;;/m0../s1
  • Key:SUKULMJPMHYWKC-GMMLHHOXSA-L

Dacuronium bromide (INN, BAN) (developmental code name NB-68) is an aminosteroid neuromuscular blocking agent which was never marketed.[1][2][3][4][5] It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).[2]

References

[edit]
  1. Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 647–. ISBN 978-1-4757-2085-3.
  2. 1 2 Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 90–. ISBN 978-94-011-4439-1.
  3. Progress in Medicinal Chemistry. Elsevier. 1 January 1979. pp. 102–. ISBN 978-0-08-086264-4.
  4. Maclagan J (1976). "Competitive neuromuscular blocking drugs.". Neuromuscular Junction. Berlin, Heidelberg: Springer. pp. 421–486. ISBN 978-3-642-45476-9.
  5. Kharkevich DA (6 December 2012). New Neuromuscular Blocking Agents: Basic and Applied Aspects. Springer Science & Business Media. pp. 201–202, 213. ISBN 978-3-642-70682-0.